Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 1921 to 1931 of 1931 entries
Sorted by: Best Match Show Resources per page
Late and very late relapsed acute lymphoblastic leukemia: clinical and molecular features, and treatment outcomes.

Blood cancer journal

Aldoss I, Pillai R, Yang D, Yang L, Arslan S, Mokhtari S, Malki MMA, Salhotra A, Shahani S, Ali H, Mei M, Artz A, Snyder D, Afkhami M, Armenian S, Stein A, Marcucci G, Forman SJ, Nakamura R, Pullarkat V.
PMID: 34215723
Blood Cancer J. 2021 Jul 02;11(7):125. doi: 10.1038/s41408-021-00516-1.

No abstract available.

Cite
Aldoss I, Pillai R, Yang D, et al. Late and very late relapsed acute lymphoblastic leukemia: clinical and molecular features, and treatment outcomes. Blood Cancer J. 2021;11(7):125doi: 10.1038/s41408-021-00516-1.
Aldoss, I., Pillai, R., Yang, D., Yang, L., Arslan, S., Mokhtari, S., Malki, M. M. A., Salhotra, A., Shahani, S., Ali, H., Mei, M., Artz, A., Snyder, D., Afkhami, M., Armenian, S., Stein, A., Marcucci, G., Forman, S. J., Nakamura, R., & Pullarkat, V. (2021). Late and very late relapsed acute lymphoblastic leukemia: clinical and molecular features, and treatment outcomes. Blood cancer journal, 11(7), 125. https://doi.org/10.1038/s41408-021-00516-1
Aldoss, Ibrahim, et al. "Late and very late relapsed acute lymphoblastic leukemia: clinical and molecular features, and treatment outcomes." Blood cancer journal vol. 11,7 (2021): 125. doi: https://doi.org/10.1038/s41408-021-00516-1
Aldoss I, Pillai R, Yang D, Yang L, Arslan S, Mokhtari S, Malki MMA, Salhotra A, Shahani S, Ali H, Mei M, Artz A, Snyder D, Afkhami M, Armenian S, Stein A, Marcucci G, Forman SJ, Nakamura R, Pullarkat V. Late and very late relapsed acute lymphoblastic leukemia: clinical and molecular features, and treatment outcomes. Blood Cancer J. 2021 Jul 02;11(7):125. doi: 10.1038/s41408-021-00516-1. PMID: 34215723; PMCID: PMC8253853.
Copy Download .nbib Format: NLM
Integrative Tumor and Immune Cell Multi-omic Analyses Predict Response to Immune Checkpoint Blockade in Melanoma.

Cell reports. Medicine

Anagnostou V, Bruhm DC, Niknafs N, White JR, Shao XM, Sidhom JW, Stein J, Tsai HL, Wang H, Belcaid Z, Murray J, Balan A, Ferreira L, Ross-Macdonald P, Wind-Rotolo M, Baras AS, Taube J, Karchin R, Scharpf RB, Grasso C, Ribas A, Pardoll DM, Topalian SL, Velculescu VE.
PMID: 33294860
Cell Rep Med. 2020 Nov 17;1(8):100139. doi: 10.1016/j.xcrm.2020.100139. eCollection 2020 Nov 17.

In this study, we incorporate analyses of genome-wide sequence and structural alterations with pre- and on-therapy transcriptomic and T cell repertoire features in immunotherapy-naive melanoma patients treated with immune checkpoint blockade. Although tumor mutation burden is associated with improved...

Cite
Anagnostou V, Bruhm DC, Niknafs N, et al. Integrative Tumor and Immune Cell Multi-omic Analyses Predict Response to Immune Checkpoint Blockade in Melanoma. Cell Rep Med. 2020;1(8):100139doi: 10.1016/j.xcrm.2020.100139.
Anagnostou, V., Bruhm, D. C., Niknafs, N., White, J. R., Shao, X. M., Sidhom, J. W., Stein, J., Tsai, H. L., Wang, H., Belcaid, Z., Murray, J., Balan, A., Ferreira, L., Ross-Macdonald, P., Wind-Rotolo, M., Baras, A. S., Taube, J., Karchin, R., Scharpf, R. B., Grasso, C., Ribas, A., Pardoll, D. M., Topalian, S. L., & Velculescu, V. E. (2020). Integrative Tumor and Immune Cell Multi-omic Analyses Predict Response to Immune Checkpoint Blockade in Melanoma. Cell reports. Medicine, 1(8), 100139. https://doi.org/10.1016/j.xcrm.2020.100139
Anagnostou, Valsamo, et al. "Integrative Tumor and Immune Cell Multi-omic Analyses Predict Response to Immune Checkpoint Blockade in Melanoma." Cell reports. Medicine vol. 1,8 (2020): 100139. doi: https://doi.org/10.1016/j.xcrm.2020.100139
Anagnostou V, Bruhm DC, Niknafs N, White JR, Shao XM, Sidhom JW, Stein J, Tsai HL, Wang H, Belcaid Z, Murray J, Balan A, Ferreira L, Ross-Macdonald P, Wind-Rotolo M, Baras AS, Taube J, Karchin R, Scharpf RB, Grasso C, Ribas A, Pardoll DM, Topalian SL, Velculescu VE. Integrative Tumor and Immune Cell Multi-omic Analyses Predict Response to Immune Checkpoint Blockade in Melanoma. Cell Rep Med. 2020 Nov 17;1(8):100139. doi: 10.1016/j.xcrm.2020.100139. eCollection 2020 Nov 17. PMID: 33294860; PMCID: PMC7691441.
Copy Download .nbib Format: NLM
Directional sound source modeling using the adjoint Euler equations in a finite-difference time-domain approach.

The Journal of the Acoustical Society of America

Stein L, Straube F, Weinzierl S, Lemke M.
PMID: 33261372
J Acoust Soc Am. 2020 Nov;148(5):3075. doi: 10.1121/10.0002425.

An adjoint-based approach for synthesizing complex sound sources by discrete, grid-based monopoles in finite-difference time-domain simulations is presented. Previously, Stein, Straube, Sesterhenn, Weinzierl, and Lemke [(2019). J. Acoust. Soc. Am. 146(3), 1774-1785] demonstrated that the approach allows one to...

Cite
Stein L, Straube F, Weinzierl S, et al. Directional sound source modeling using the adjoint Euler equations in a finite-difference time-domain approach. J Acoust Soc Am. 2020;148(5):3075doi: 10.1121/10.0002425.
Stein, L., Straube, F., Weinzierl, S., & Lemke, M. (2020). Directional sound source modeling using the adjoint Euler equations in a finite-difference time-domain approach. The Journal of the Acoustical Society of America, 148(5), 3075. https://doi.org/10.1121/10.0002425
Stein, Lewin, et al. "Directional sound source modeling using the adjoint Euler equations in a finite-difference time-domain approach." The Journal of the Acoustical Society of America vol. 148,5 (2020): 3075. doi: https://doi.org/10.1121/10.0002425
Stein L, Straube F, Weinzierl S, Lemke M. Directional sound source modeling using the adjoint Euler equations in a finite-difference time-domain approach. J Acoust Soc Am. 2020 Nov;148(5):3075. doi: 10.1121/10.0002425. PMID: 33261372.
Copy Download .nbib Format: NLM
Efficacy of Pazopanib With or Without Gemcitabine in Patients With Anthracycline- and/or Ifosfamide-Refractory Soft Tissue Sarcoma: Final Results of the PAPAGEMO Phase 2 Randomized Clinical Trial.

JAMA oncology

Schmoll HJ, Lindner LH, Reichardt P, Heißner K, Kopp HG, Kessler T, Mayer-Steinacker R, Rüssel J, Egerer G, Crysandt M, Kasper B, Niederwieser D, Kunitz A, Eigendorff E, Petersen I, Steighardt J, Cygon F, Meinert F, Stein A.
PMID: 33355646
JAMA Oncol. 2021 Feb 01;7(2):255-262. doi: 10.1001/jamaoncol.2020.6564.

IMPORTANCE: Pazopanib and gemcitabine have shown good tolerability, albeit modest single-agent activity in pretreated soft tissue sarcoma. A combined regimen to improve outcomes is required.OBJECTIVE: To determine the efficacy of gemcitabine and pazopanib compared with pazopanib alone.DESIGN, SETTING, AND...

Cite
Schmoll HJ, Lindner LH, Reichardt P, et al. Efficacy of Pazopanib With or Without Gemcitabine in Patients With Anthracycline- and/or Ifosfamide-Refractory Soft Tissue Sarcoma: Final Results of the PAPAGEMO Phase 2 Randomized Clinical Trial. JAMA Oncol. 2021;7(2):255-262doi: 10.1001/jamaoncol.2020.6564.
Schmoll, H. J., Lindner, L. H., Reichardt, P., Heißner, K., Kopp, H. G., Kessler, T., Mayer-Steinacker, R., Rüssel, J., Egerer, G., Crysandt, M., Kasper, B., Niederwieser, D., Kunitz, A., Eigendorff, E., Petersen, I., Steighardt, J., Cygon, F., Meinert, F., & Stein, A. (2021). Efficacy of Pazopanib With or Without Gemcitabine in Patients With Anthracycline- and/or Ifosfamide-Refractory Soft Tissue Sarcoma: Final Results of the PAPAGEMO Phase 2 Randomized Clinical Trial. JAMA oncology, 7(2), 255-262. https://doi.org/10.1001/jamaoncol.2020.6564
Schmoll, Hans-Joachim, et al. "Efficacy of Pazopanib With or Without Gemcitabine in Patients With Anthracycline- and/or Ifosfamide-Refractory Soft Tissue Sarcoma: Final Results of the PAPAGEMO Phase 2 Randomized Clinical Trial." JAMA oncology vol. 7,2 (2021): 255-262. doi: https://doi.org/10.1001/jamaoncol.2020.6564
Schmoll HJ, Lindner LH, Reichardt P, Heißner K, Kopp HG, Kessler T, Mayer-Steinacker R, Rüssel J, Egerer G, Crysandt M, Kasper B, Niederwieser D, Kunitz A, Eigendorff E, Petersen I, Steighardt J, Cygon F, Meinert F, Stein A. Efficacy of Pazopanib With or Without Gemcitabine in Patients With Anthracycline- and/or Ifosfamide-Refractory Soft Tissue Sarcoma: Final Results of the PAPAGEMO Phase 2 Randomized Clinical Trial. JAMA Oncol. 2021 Feb 01;7(2):255-262. doi: 10.1001/jamaoncol.2020.6564. PMID: 33355646; PMCID: PMC7758834.
Copy Download .nbib Format: NLM
[Quality of life for wearers of a suprapubic or transurethral bladder catheter as lifelong permanent care].

Der Urologe. Ausg. A

Wiedemann A, Gedding C, Heese M, Stein J, Manseck A, Kirschner-Hermanns R, Karstedt H, Schorn A, Wagner A, Moll V, Unger U, Eisenhardt A, Bannowsky A, Linné C, Wirz S, Brammen E, Heppner HJ.
PMID: 34605933
Urologe A. 2021 Oct 04; doi: 10.1007/s00120-021-01642-1. Epub 2021 Oct 04.

BACKGROUND: The insertion of a Foley catheter (FC) or a suprapubic catheter (SPC) in lifelong intent is an intervention with significant complications, comorbidities and impact on the further life that has not yet been analyzed.METHODOLOGY: The analysis was based...

Cite
Wiedemann A, Gedding C, Heese M, et al. Lebensqualität bei Trägern eines suprapubischen oder transurethralen Harnblasenkatheters als lebenslange Dauerversorgung. [Quality of life for wearers of a suprapubic or transurethral bladder catheter as lifelong permanent care]. Urologe A. 2021;doi: 10.1007/s00120-021-01642-1.
Wiedemann, A., Gedding, C., Heese, M., Stein, J., Manseck, A., Kirschner-Hermanns, R., Karstedt, H., Schorn, A., Wagner, A., Moll, V., Unger, U., Eisenhardt, A., Bannowsky, A., Linné, C., Wirz, S., Brammen, E., & Heppner, H. J. (2021). Lebensqualität bei Trägern eines suprapubischen oder transurethralen Harnblasenkatheters als lebenslange Dauerversorgung. [Quality of life for wearers of a suprapubic or transurethral bladder catheter as lifelong permanent care]. Der Urologe. Ausg. A, . https://doi.org/10.1007/s00120-021-01642-1
Wiedemann, A, et al. "Lebensqualität bei Trägern eines suprapubischen oder transurethralen Harnblasenkatheters als lebenslange Dauerversorgung." [Quality of life for wearers of a suprapubic or transurethral bladder catheter as lifelong permanent care]. Der Urologe. Ausg. A vol. (2021). doi: https://doi.org/10.1007/s00120-021-01642-1
Wiedemann A, Gedding C, Heese M, Stein J, Manseck A, Kirschner-Hermanns R, Karstedt H, Schorn A, Wagner A, Moll V, Unger U, Eisenhardt A, Bannowsky A, Linné C, Wirz S, Brammen E, Heppner HJ. Lebensqualität bei Trägern eines suprapubischen oder transurethralen Harnblasenkatheters als lebenslange Dauerversorgung. [Quality of life for wearers of a suprapubic or transurethral bladder catheter as lifelong permanent care]. Urologe A. 2021 Oct 04; doi: 10.1007/s00120-021-01642-1. Epub 2021 Oct 04. German. PMID: 34605933.
Copy Download .nbib Format: NLM
SIRT6-CBP-dependent nuclear Tau accumulation and its role in protein synthesis.

Cell reports

Portillo M, Eremenko E, Kaluski S, Garcia-Venzor A, Onn L, Stein D, Slobodnik Z, Zaretsky A, Ueberham U, Einav M, Brückner MK, Arendt T, Toiber D.
PMID: 33910019
Cell Rep. 2021 Apr 27;35(4):109035. doi: 10.1016/j.celrep.2021.109035.

Several neurodegenerative diseases present Tau accumulation as the main pathological marker. Tau post-translational modifications such as phosphorylation and acetylation are increased in neurodegeneration. Here, we show that Tau hyper-acetylation at residue 174 increases its own nuclear presence and is...

Cite
Portillo M, Eremenko E, Kaluski S, et al. SIRT6-CBP-dependent nuclear Tau accumulation and its role in protein synthesis. Cell Rep. 2021;35(4):109035doi: 10.1016/j.celrep.2021.109035.
Portillo, M., Eremenko, E., Kaluski, S., Garcia-Venzor, A., Onn, L., Stein, D., Slobodnik, Z., Zaretsky, A., Ueberham, U., Einav, M., Brückner, M. K., Arendt, T., & Toiber, D. (2021). SIRT6-CBP-dependent nuclear Tau accumulation and its role in protein synthesis. Cell reports, 35(4), 109035. https://doi.org/10.1016/j.celrep.2021.109035
Portillo, Miguel, et al. "SIRT6-CBP-dependent nuclear Tau accumulation and its role in protein synthesis." Cell reports vol. 35,4 (2021): 109035. doi: https://doi.org/10.1016/j.celrep.2021.109035
Portillo M, Eremenko E, Kaluski S, Garcia-Venzor A, Onn L, Stein D, Slobodnik Z, Zaretsky A, Ueberham U, Einav M, Brückner MK, Arendt T, Toiber D. SIRT6-CBP-dependent nuclear Tau accumulation and its role in protein synthesis. Cell Rep. 2021 Apr 27;35(4):109035. doi: 10.1016/j.celrep.2021.109035. PMID: 33910019.
Copy Download .nbib Format: NLM
Association Between Preterm-Birth Phenotypes and Differential Morbidity, Growth, and Neurodevelopment at Age 2 Years: Results From the INTERBIO-21st Newborn Study.

JAMA pediatrics

Villar J, Restrepo-Méndez MC, McGready R, Barros FC, Victora CG, Munim S, Papageorghiou AT, Ochieng R, Craik R, Barsosio HC, Berkley JA, Carvalho M, Fernandes M, Cheikh Ismail L, Lambert A, Norris SA, Ohuma EO, Stein A, Tshivuila-Matala COO, Zondervan KT, Winsey A, Nosten F, Uauy R, Bhutta ZA, Kennedy SH.
PMID: 33646288
JAMA Pediatr. 2021 May 01;175(5):483-493. doi: 10.1001/jamapediatrics.2020.6087.

IMPORTANCE: The etiologic complexities of preterm birth remain inadequately understood, which may impede the development of better preventative and treatment measures.OBJECTIVE: To examine the association between specific preterm-birth phenotypes and clinical, growth, and neurodevelopmental differences among preterm newborns compared...

Cite
Villar J, Restrepo-Méndez MC, McGready R, et al. Association Between Preterm-Birth Phenotypes and Differential Morbidity, Growth, and Neurodevelopment at Age 2 Years: Results From the INTERBIO-21st Newborn Study. JAMA Pediatr. 2021;175(5):483-493doi: 10.1001/jamapediatrics.2020.6087.
Villar, J., Restrepo-Méndez, M. C., McGready, R., Barros, F. C., Victora, C. G., Munim, S., Papageorghiou, A. T., Ochieng, R., Craik, R., Barsosio, H. C., Berkley, J. A., Carvalho, M., Fernandes, M., Cheikh Ismail, L., Lambert, A., Norris, S. A., Ohuma, E. O., Stein, A., Tshivuila-Matala, C. O. O., Zondervan, K. T., Winsey, A., Nosten, F., Uauy, R., Bhutta, Z. A., & Kennedy, S. H. (2021). Association Between Preterm-Birth Phenotypes and Differential Morbidity, Growth, and Neurodevelopment at Age 2 Years: Results From the INTERBIO-21st Newborn Study. JAMA pediatrics, 175(5), 483-493. https://doi.org/10.1001/jamapediatrics.2020.6087
Villar, Jose, et al. "Association Between Preterm-Birth Phenotypes and Differential Morbidity, Growth, and Neurodevelopment at Age 2 Years: Results From the INTERBIO-21st Newborn Study." JAMA pediatrics vol. 175,5 (2021): 483-493. doi: https://doi.org/10.1001/jamapediatrics.2020.6087
Villar J, Restrepo-Méndez MC, McGready R, Barros FC, Victora CG, Munim S, Papageorghiou AT, Ochieng R, Craik R, Barsosio HC, Berkley JA, Carvalho M, Fernandes M, Cheikh Ismail L, Lambert A, Norris SA, Ohuma EO, Stein A, Tshivuila-Matala COO, Zondervan KT, Winsey A, Nosten F, Uauy R, Bhutta ZA, Kennedy SH. Association Between Preterm-Birth Phenotypes and Differential Morbidity, Growth, and Neurodevelopment at Age 2 Years: Results From the INTERBIO-21st Newborn Study. JAMA Pediatr. 2021 May 01;175(5):483-493. doi: 10.1001/jamapediatrics.2020.6087. PMID: 33646288; PMCID: PMC7922239.
Copy Download .nbib Format: NLM
Lipid Droplets Protect Human β-Cells From Lipotoxicity-Induced Stress and Cell Identity Changes.

Diabetes

Tong X, Stein R.
PMID: 34433630
Diabetes. 2021 Nov;70(11):2595-2607. doi: 10.2337/db21-0261. Epub 2021 Aug 25.

Free fatty acids (FFAs) are often stored in lipid droplet (LD) depots for eventual metabolic and/or synthetic use in many cell types, such a muscle, liver, and fat. In pancreatic islets, overt LD accumulation was detected in humans but...

Cite
Tong X, Stein R. Lipid Droplets Protect Human β-Cells From Lipotoxicity-Induced Stress and Cell Identity Changes. Diabetes. 2021;70(11):2595-2607doi: 10.2337/db21-0261.
Tong, X., & Stein, R. (2021). Lipid Droplets Protect Human β-Cells From Lipotoxicity-Induced Stress and Cell Identity Changes. Diabetes, 70(11), 2595-2607. https://doi.org/10.2337/db21-0261
Tong, Xin, and Stein, Roland. "Lipid Droplets Protect Human β-Cells From Lipotoxicity-Induced Stress and Cell Identity Changes." Diabetes vol. 70,11 (2021): 2595-2607. doi: https://doi.org/10.2337/db21-0261
Tong X, Stein R. Lipid Droplets Protect Human β-Cells From Lipotoxicity-Induced Stress and Cell Identity Changes. Diabetes. 2021 Nov;70(11):2595-2607. doi: 10.2337/db21-0261. Epub 2021 Aug 25. PMID: 34433630; PMCID: PMC8564404.
Copy Download .nbib Format: NLM
A Brief Home-Based Parenting Intervention to Reduce Behavior Problems in Young Children: A Pragmatic Randomized Clinical Trial.

JAMA pediatrics

O'Farrelly C, Watt H, Babalis D, Bakermans-Kranenburg MJ, Barker B, Byford S, Ganguli P, Grimas E, Iles J, Mattock H, McGinley J, Phillips C, Ryan R, Scott S, Smith J, Stein A, Stevens E, van IJzendoorn MH, Warwick J, Ramchandani PG.
PMID: 33720329
JAMA Pediatr. 2021 Jun 01;175(6):567-576. doi: 10.1001/jamapediatrics.2020.6834.

IMPORTANCE: Behavior problems are one of the most common mental health disorders in childhood and can undermine children's health, education, and employment outcomes into adulthood. There are few effective interventions for early childhood.OBJECTIVE: To test the clinical effectiveness of...

Cite
O'Farrelly C, Watt H, Babalis D, et al. A Brief Home-Based Parenting Intervention to Reduce Behavior Problems in Young Children: A Pragmatic Randomized Clinical Trial. JAMA Pediatr. 2021;175(6):567-576doi: 10.1001/jamapediatrics.2020.6834.
O'Farrelly, C., Watt, H., Babalis, D., Bakermans-Kranenburg, M. J., Barker, B., Byford, S., Ganguli, P., Grimas, E., Iles, J., Mattock, H., McGinley, J., Phillips, C., Ryan, R., Scott, S., Smith, J., Stein, A., Stevens, E., van IJzendoorn, M. H., Warwick, J., & Ramchandani, P. G. (2021). A Brief Home-Based Parenting Intervention to Reduce Behavior Problems in Young Children: A Pragmatic Randomized Clinical Trial. JAMA pediatrics, 175(6), 567-576. https://doi.org/10.1001/jamapediatrics.2020.6834
O'Farrelly, Christine, et al. "A Brief Home-Based Parenting Intervention to Reduce Behavior Problems in Young Children: A Pragmatic Randomized Clinical Trial." JAMA pediatrics vol. 175,6 (2021): 567-576. doi: https://doi.org/10.1001/jamapediatrics.2020.6834
O'Farrelly C, Watt H, Babalis D, Bakermans-Kranenburg MJ, Barker B, Byford S, Ganguli P, Grimas E, Iles J, Mattock H, McGinley J, Phillips C, Ryan R, Scott S, Smith J, Stein A, Stevens E, van IJzendoorn MH, Warwick J, Ramchandani PG. A Brief Home-Based Parenting Intervention to Reduce Behavior Problems in Young Children: A Pragmatic Randomized Clinical Trial. JAMA Pediatr. 2021 Jun 01;175(6):567-576. doi: 10.1001/jamapediatrics.2020.6834. PMID: 33720329; PMCID: PMC7961467.
Copy Download .nbib Format: NLM
Postoperative tonsil/adenoidectomy bleeding management in patients with diagnosed bleeding disorders.

Laryngoscope investigative otolaryngology

Pai K, Desai H, Stein D, Cole S.
PMID: 34401515
Laryngoscope Investig Otolaryngol. 2021 Jun 10;6(4):872-877. doi: 10.1002/lio2.589. eCollection 2021 Aug.

OBJECTIVE: Tonsil/adenoidectomy (T/A) is a commonly performed procedure with an average post-tonsillectomy bleed (PTB) rate between 3 and 5%. Patients with bleeding disorders (BDs) are believed to have an increased risk of PTB. We hypothesize that our medical management...

Cite
Pai K, Desai H, Stein D, et al. Postoperative tonsil/adenoidectomy bleeding management in patients with diagnosed bleeding disorders. Laryngoscope Investig Otolaryngol. 2021;6(4):872-877doi: 10.1002/lio2.589.
Pai, K., Desai, H., Stein, D., & Cole, S. (2021). Postoperative tonsil/adenoidectomy bleeding management in patients with diagnosed bleeding disorders. Laryngoscope investigative otolaryngology, 6(4), 872-877. https://doi.org/10.1002/lio2.589
Pai, Kavya, et al. "Postoperative tonsil/adenoidectomy bleeding management in patients with diagnosed bleeding disorders." Laryngoscope investigative otolaryngology vol. 6,4 (2021): 872-877. doi: https://doi.org/10.1002/lio2.589
Pai K, Desai H, Stein D, Cole S. Postoperative tonsil/adenoidectomy bleeding management in patients with diagnosed bleeding disorders. Laryngoscope Investig Otolaryngol. 2021 Jun 10;6(4):872-877. doi: 10.1002/lio2.589. eCollection 2021 Aug. PMID: 34401515; PMCID: PMC8356851.
Copy Download .nbib Format: NLM
The four habits coding scheme: Validation of an instrument to assess clinicians' communication behavior.

Krupat E, Frankel R, Stein T, Irish J.
UIID-AD: 519
2006;62:38-45. doi: 10.1016/j.pec.2005.04.015.

Objective: To present preliminary evidence for the reliability and validity of the Four Habits Coding Scheme (4HCS), an instrument based on a teaching model used widely throughout Kaiser Permanente to improve clinicians' communication skills. Methods: One hundred videotaped primary...

Cite
Krupat E, Frankel R, Stein T, et al. The four habits coding scheme: Validation of an instrument to assess clinicians' communication behavior. 2006;62:38-45doi: 10.1016/j.pec.2005.04.015.
Krupat, E., Frankel, R., Stein, T., & Irish, J. (2006). The four habits coding scheme: Validation of an instrument to assess clinicians' communication behavior. 6238-45. https://doi.org/10.1016/j.pec.2005.04.015
Krupat, E, et al. "The four habits coding scheme: Validation of an instrument to assess clinicians' communication behavior." vol. 62 (2006): 38-45. doi: https://doi.org/10.1016/j.pec.2005.04.015
Krupat E, Frankel R, Stein T, Irish J. The four habits coding scheme: Validation of an instrument to assess clinicians' communication behavior. 2006;62:38-45. doi: 10.1016/j.pec.2005.04.015. UIID-AD: 519.
Copy Download .nbib Format: NLM
Showing 1921 to 1931 of 1931 entries